Biomarkers for predicting atrial fibrillation: An explorative sub-analysis of the randomised SCREEN-AF trial

References

• Riley AB, Manning WJ. Atrial fibrillation: an epidemic in the elderly. Expert Rev Cardiovasc Ther. 2011;9(8):1–8. doi: 10.1586/erc.11.107.
   PubMedGoogle Scholar
• Weng L-C, Preis SR, Hulme OL, et al. Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation. Circulation. 2018;137(10):1027–1038. doi: 10.1161/CIRCULATIONAHA.117.031431.
   PubMed Web of Science ®Google Scholar
• Borowsky LH, Regan S, Chang Y, et al. First diagnosis of atrial fibrillation at the time of stroke. Cerebrovasc Dis. 2017;43(3-4):192–199. doi: 10.1159/000457809.
   PubMed Web of Science ®Google Scholar
• Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377–387. doi: 10.1016/S1474-4422(15)70027-X.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42(5):373–498. doi: 10.1093/eurheartj/ehaa612.
   Web of Science ®Google Scholar
• Davidson KW, Barry MJ, Mangione CM, et al. Screening for atrial fibrillation: US preventive services task force recommendation statement. J Am Med Assoc. 2022;327(4):360–367. doi: 10.1001/jama.2021.23732.
   PubMed Web of Science ®Google Scholar
• Atlas SJ, Ashburner JM, Chang Y, et al. Screening for undiagnosed atrial fibrillation using a single-lead electrocardiogram at primary care visits: patient uptake and practitioner perspectives from the VITAL-AF trial. BMC Prim Care. 2023;24(1):135. doi: 10.1186/s12875-023-02087-5.
   PubMedGoogle Scholar
• Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost. 2013;110(2):213–222. doi: 10.1160/TH13-02-0165.
   PubMed Web of Science ®Google Scholar
• Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. Screening for atrial fibrillation in the older population: a randomized clinical trial. JAMA Cardiol. 2021;6(5):558–567. doi: 10.1001/jamacardio.2021.0038.
   PubMed Web of Science ®Google Scholar
• Sepehri Shamloo A, Bollmann A, Dagres N, et al. Natriuretic peptides: biomarkers for atrial fibrillation management. Clin Res Cardiol. 2020;109(8):957–966. doi: 10.1007/s00392-020-01608-x.
   PubMed Web of Science ®Google Scholar
• Ardhianto P, Yuniadi Y. Biomarkers of atrial fibrillation: which one is a true marker? Cardiol Res Pract. 2019;2019:1–8. doi: 10.1155/2019/8302326.
   Web of Science ®Google Scholar
• Fu Y, Pan Y, Gao Y, et al. Predictive value of CHA2DS2-VASc score combined with hs-CRP for new-onset atrial fibrillation in elderly patients with acute myocardial infarction. BMC Cardiovasc Disord. 2021;21(1):175. doi: 10.1186/s12872-021-01978-8.
   PubMedGoogle Scholar
• Yagmur E, Sckaer JH, Koek GH, et al. Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients. J Transl Med. 2019;17(1):415. doi: 10.1186/s12967-019-02165-2.
   PubMed Web of Science ®Google Scholar
• Amar D, Zhang H, Tan KS, et al. A brain natriuretic peptide-based prediction model for atrial fibrillation after thoracic surgery: development and internal validation. J Thorac Cardiovasc Surg. 2019;157(6):2493–2499.e1. doi: 10.1016/j.jtcvs.2019.01.075.
   PubMed Web of Science ®Google Scholar
• Wasser K, Weber-Krüger M, Gröschel S, et al. Brain natriuretic peptide and discovery of atrial fibrillation After stroke: a subanalysis of the Find-AFRANDOMISED trial. Stroke. 2020;51(2):395–401. doi: 10.1161/STROKEAHA.119.026496.
   PubMed Web of Science ®Google Scholar
• ROME. [cited 2024 Feb 28]. Available from: https://rome.phri.ca/SCREEN-AF/.
   Google Scholar
• Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127(1):95.e11-7–95.e17. doi: 10.1016/j.amjmed.2013.10.003.
   PubMed Web of Science ®Google Scholar
• Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol. 2013;112(4):520–524. doi: 10.1016/j.amjcard.2013.04.017.
   PubMed Web of Science ®Google Scholar
• Sramko M, Wichterle D, Melenovsky V, et al. Independent effect of atrial fibrillation on natriuretic peptide release. Clin Res Cardiol. 2019;108(2):142–149. doi: 10.1007/s00392-018-1332-1.
   PubMed Web of Science ®Google Scholar
• Kara K, Geisel MH, Möhlenkamp S, et al. B-type natriuretic peptide for incident atrial fibrillation-The Heinz Nixdorf recall study. J Cardiol. 2015;65(6):453–458. doi: 10.1016/j.jjcc.2014.08.003.
   PubMed Web of Science ®Google Scholar
• Seegers J, Zabel M, Grüter T, et al. Natriuretic peptides for the detection of paroxysmal atrial fibrillation. Open Heart. 2015;2(1):e000182. doi: 10.1136/openhrt-2014-000182.
   PubMedGoogle Scholar
• Karolina I, Michał K, Marzenna Z. MR-proANP level predicts new onset atrial fibrillation in patients with acute myocardial infarction. Biomarkers. 2020;25(7):573–577. doi: 10.1080/1354750X.2020.1814414.
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121(2):200–207. doi: 10.1161/CIRCULATIONAHA.109.882241.
   PubMed Web of Science ®Google Scholar
• Xing LY, Diederichsen SZ, Højberg S, et al. Effects of atrial fibrillation screening According to N-terminal pro-B-Type natriuretic peptide: a secondary analysis of the randomized LOOP study. Circulation. 2023;147(24):1788–1797. doi: 10.1161/CIRCULATIONAHA.123.064361.
   PubMed Web of Science ®Google Scholar
• Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace. 2020;22(1):24–32. doi: 10.1093/europace/euz255.
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Januzzi JL. The past, the present, and the future of natriuretic peptides in the diagnosis of heart failure. European Heart Journal Supplements. 2018;20(suppl_G):G11–G20. doi: 10.1093/eurheartj/suy024.
   Web of Science ®Google Scholar
• Merino-Merino A, Saez-Maleta R, Salgado-Aranda R, et al. Biomarkers in atrial fibrillation and heart failure with non-reduced ejection fraction: diagnostic application and new cut-off points. Heart Lung. 2020;49(4):388–392. doi: 10.1016/j.hrtlng.2020.02.043.
   PubMed Web of Science ®Google Scholar
• Eckstein J, Potocki M, Murray K, et al. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea. Heart. 2012;98(20):1518–1522. doi: 10.1136/heartjnl-2012-302260.
   PubMed Web of Science ®Google Scholar
• Wachter R, Weber-Krüger M, Hamann GF, et al. Long-Term follow-up of enhanced Holter-Electrocardiography monitoring in acute ischemic stroke. J Stroke. 2022;24(1):98–107. doi: 10.5853/jos.2021.01207.
   PubMed Web of Science ®Google Scholar
• Werhahn SM, Becker C, Mende M, et al. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Fail. 2022;9(1):100–109. doi: 10.1002/ehf2.13703.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Hanß S, Kraus M, et al. The DZHK research platform: maximisation of scientific value by enabling access to health data and biological samples collected in cardiovascular clinical studies. Clin Res Cardiol. 2023;112(7):923–941. doi: 10.1007/s00392-023-02177-5.
   PubMed Web of Science ®Google Scholar